Previous 10 | Next 10 |
AIM ImmunoTech (NYSEMKT: AIM ) +20% on discussing the potential role of Ampligen for use against the Wuhan 2019 Novel Coronavirus. More news on: AIM ImmunoTech Inc., TransEnterix, Inc., Shopify Inc., Stocks on the move, , Read more ...
LONDON and REDWOOD CITY, Calif., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or the "Company," today announced that it is distributing approximately 1.2 cents cash per Contingent Value Right (“CVR”), a total of approximately $4...
OCALA, FL / ACCESSWIRE / February 12, 2020 / AIM ImmunoTech Inc. (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers, today announced that its Chief Executive Officer, Th...
LONDON and VANCOUVER, British Columbia, Feb. 12, 2020 (GLOBE NEWSWIRE) -- Mkango Resources Ltd. (AIM/TSX-V: MKA) (the "Company" or "Mkango"), is pleased to announce results from its recent mineral exploration programme at the Thambani project in southern Malawi. Assay results from 128 r...
DIDCOT, UK / ACCESSWIRE / February 11, 2020 / Altus Strategies Plc (AIM:ALS)(TSXV:ALTS), the Africa focused project and royalty generator, announces that it has received 15 million fully paid ordinary shares (" First Shares ") in ASX listed Canyon Resources Ltd (" Canyon "). The First Shares...
Ampligen ® obtained 100% survival rate at clinically achievable human dosage levels for SARS in animal experiments Ampligen key to proposed broad-spectrum ‘universal’ coronavirus vaccine OCALA, Fla., Feb. 11, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE...
Ampligen® obtained 100% survival rate at clinically achievable human dosage levels for SARS in animal experiments Ampligen key to proposed broad-spectrum 'universal' coronavirus vaccine OCALA, FL / ACCESSWIRE / February 11, 2020 / AIM ImmunoTech Inc. (NYSE American:AIM) today ...
NEW STUDY DEMONSTRATES POTENTIAL FOR PARSORTIX IN MELANOMA PROGNOSTICATION AND TREATMENT RESPONSE Parsortix out-performed alternative systems in head to head comparisons and was selected for molecular analysis in the study Parsortix CTC score linked to progression-free and overall surv...
LONDON and REDWOOD CITY, Calif., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or the "Company," a clinical stage biopharmaceutical company focused on rare diseases, today announced that it has entered into a $5 million convertible equity fina...
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics to Receive $1.0 Million Milestone Payment from Eurofarma Milestone Based on Achievement of Patient Enrolment Target in Phase 3 Clinical Trials of Ridinilazole Oxford, UK...
News, Short Squeeze, Breakout and More Instantly...
OCALA, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the publication of new pre-clinical data concerning the company’s drug Ampligen as part of a combinational therapy in the...
OCALA, Fla., June 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Pitch Con...
OCALA, Fla., June 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Lunch Break Series ...